Antimicrobial pipeline DEINOVE focuses on rare, uncultivable bacteria to develop new antibiotics, antifungals, antivirals and antiparasitics with a Phase II antibiotic candidate for severe Clostridioides difficile infections, presenting a potential to partner on early access programs, co-development or licensing of novel antimicrobial assets.

Unique microbial library Maintains a proprietary collection of 10,000 rare strains and thousands of bacterial extracts, offering a rich source for collaborative target discovery, screening partnerships, and custom compound libraries for pharma or biotech customers seeking novel antimicrobial candidates.

Industrial production Developed bacterial micro-factories to scale production of complex, low-concentration compounds that are difficult to synthesize chemically, creating opportunities for manufacturing partnerships, process development, and tech transfer deals with CDMOs or bioprocess firms.

Strategic collaborations Recent and ongoing partnerships, including with Calibr and potential DSM-backed programs, indicate openness to co-development and alliance models for infectious disease programs, signaling a buyer-ready path for collaboration and investment discussions.

Cosmetics to biotech crossover Past and ongoing initiatives in bio-based cosmetic actives (Luminity) alongside antimicrobial programs suggest opportunities to cross-sell microbial-derived ingredients or engage in synergistic R&D partnerships spanning health, cosmetics and consumer care sectors.